arrakis therapeutics careers

She most recently served as Vice President, Finance and Strategy and Treasurer at Arrakis Therapeutics. Find high paying available jobs at Arrakis Therapeutics.For expert network information on Arrakis Therapeutics compensation and careers, use Ladders $100K + Club. Arrakis Therapeutics, Inc. operates as a pharmaceutical company. Dr. Dumas most recently served as Chief Scientific Officer of Tetraphase Pharmaceuticals where he led teams conducting drug discovery, preclinical development, CMC and commercial manufacturing. Apply to the latest jobs near you. Cellular context will usher a new generation of molecular therapeutics. Based on insights from the […] Search for more Director, Information Technology jobs … We have built a fully integrated, technology enabled platform for rational vector design, analytical characterization, and scalable manufacturing to design and develop gene therapies for diseases with well-understood underlying biology. Dr. Hargreaves is currently Corporate VP, Head Neuroscience and Imaging Research and Early Development at Celgene. Its TRYST and PEARL-seq platforms identify new RNA targets and drug candidates to treat diseases unaddressed by today's medicines. Arrakis Therapeutics investors. The company was co-founded in 2015 by CEO Michael Gilman, a former Biogen executive who co-founded and led Padlock Therapeutics … Dr. Petter is the founding CEO and current CSO of Arrakis Therapeutics. JOIN OUR TEAM. Jennifer Petter is Chief Scientific Officer/Founder at Arrakis Therapeutics Inc. See Jennifer Petter's compensation, career history, education, & memberships. She has nearly 30 years of experience in the biotech industry as a leader of emerging companies. WALTHAM, Mass.--(BUSINESS WIRE)--Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, announced today that it has appointed Amanda E. Hargrove, Ph.D., and Adrian Whitty, Ph.D., to its Scientific Advisory Board.The Arrakis SAB is now composed of eight members who provide scientific … 5 Science Park. Learn about salary, employee reviews, interviews, benefits, and work-life balance Arrakis Therapeutics expect to move their small molecule candidates into toxicology studies by 2022 to prepare for clinical trials. Your Impact at Arrakis The mission of Arrakis Therapeutics is to extend small molecule medicines into new realms of biology by discovering and developing compounds that … Apply to Associate Director, Senior Scientist, Compound Manager and more! Roche, which Arrakis had been in touch with since the 2017 J.P. Morgan Healthcare Conference, was an obvious choice for a partner. We have assembled a strong scientific, medchem, management, and commercial team based in Finland and the US. The … Marketing Communication Manager Europe. Arrakis Therapeutics Stock. Developer of a drug discovery platform intended to target RNA. Previously, Russ was Vice President of Drug Discovery at Avila Therapeutics and, upon the acquisition of Avila by Celgene in 2012, he became Celgene’s Vice President of Chemistry, a position he held until leaving to found Arrakis in 2015. Salaries posted anonymously by Spark Therapeutics employees. The company’s TRYST™ and PEARL-seq™ platforms identify new RNA targets and drug … Arrakis Therapeutics. Jacques Dumas is Senior Vice President, Discovery at Arrakis Therapeutics. Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. Arrakis Therapeutics, Inc. operates as a biopharmaceutical company. Arrakis Therapeutics - is seeking suitable candidates for the job of Associate Director, Target Biology and Translational Medicine in Waltham, MA. The company's platform integrates RNA bioinformatics, chemical biology tools, chemical and biological assays, and RNA-directed medicinal chemistry, enabling physicians to treat a range of diseases including neurology, oncology, and rare … The company’s TRYST™ and … SCIENTIFIC ADVISORS Business and Management Arrakis Therapeutics United States of America. Arrakis Therapeutics General Information Description. Arrakis Therapeutics - is seeking suitable candidates for the job of Director, Information Technology in Waltham, MA. Arrakis Therapeutics serves the healthcare sector in the United States. It’s now time to look beyond and leverage the orchestration of protein function within cells. Bone Therapeutics is a bone cell therapy company specializing in addressing unmet medical needs in the field of bone fracture repair and bone fracture prevention. Dr. Petter is the founding CEO and current CSO of Arrakis Therapeutics. The Company discovers medicines for the treatment of cancer. Developer of a drug discovery platform designed to find new points of therapeutic intervention. About Arrakis Therapeutics Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. Arrakis Therapeutics 828 Winter Street Waltham, MA 02451 E | info@arrakistx.com The company has developed a proprietary platform to identify new RNA targets and drug candidates to treat diseases unaddressed by today’s medicines. Michael Gilman, current CEO of Arrakis Therapeutics, was previously featured in C&EN's 10 Start-ups to Watch in 2015 for his company Padlock Therapeutics, which Bristol-Meyers-Squibb acquired in 2016. For 60 years, sequence and structure has been the primary lens to understand protein function. Apply to Post-doctoral Fellow, Health Science Adjunct - Human Genetics & Genomics, Scholar-postdoctoral and more! New Arrakis Therapeutics jobs added daily. Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. Roger Clark, Ph.D., is the Vice President, Discovery Sciences at Zikani Therapeutics, responsible for hit and lead optimization for our target diseases using our TURBO-ZM™ platform. The Life Sciences team advised Arrakis Therapeutics on its strategic collaboration and license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) for the discovery of RNA-targeted small molecule (rSM) drugs against a broad set of targets across all of Roche’s research and development areas.. Arrakis is a biopharmaceutical company pioneering the discovery of a new class of medicines … Larimar Therapeutics is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. "Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. Your Impact at Arrakis The mission of Arrakis Therapeutics is to extend small molecule medicines into new realms of biology by discovering and developing compounds that … Spek is an experienced biotech executive who has been a leader in corporate … Russell Petter. A free inside look at Spark Therapeutics salary trends based on 74 salaries wages for 59 jobs at Spark Therapeutics. Arrakis Therapeutics, a biopharmaceutical company focused on the discovery of new-class small molecules medicines targeting RNA, has appointed Katrine Bosley (pictured below, right) as chairman of its Board of Directors. Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. He joins with notable computational biology experience in the biotech space, most recently serving as head of computational biology at Arrakis Therapeutics and prior to that as a computational scientist leading splicing bioinformatics efforts at H3 Biomedicine. If you are a drug-hunting scientist or drug developer with interest and expertise in novel biological pathways that underlie fibrosis and neurodegeneration and are interested in Blade, please send us your resume. Previously, Jennifer was Vice President of Drug Discovery at Avila Therapeutics and, after the acquisition of Avila by Celgene in 2012, she became Celgene’s Vice President of Chemistry, a position she held until leaving to found Arrakis … Attralus, Inc., (formerly Aurora Bio) is a VC funded privately held development stage biotechnology company focused on improving the lives of systemic amyloidosis patients, through the development of novel diagnostics and therapeutics. Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. Gilman is now CEO of that start-up, Waltham, Mass.-based Arrakis Therapeutics, which was founded in September 2015 by Russell Petter, former vice president of chemistry at Celgene and now chief scientific officer for Arrakis. Flare is lighting up a new therapeutic space with an entirely different approach to decipher the biology of transcription factors to develop small molecule medicines. Our team ‘brings it’ every day for one mission: to conquer transcription factors and create cutting-edge medicines for patients. 11 Arrakis Therapeutics jobs. Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines. Arrakis Therapeutics | 5.138 følgere på LinkedIn. Our team. An experienced team of biopharmaceutical leaders. Arrakis is building a proprietary pipeline of RNA-targeted small molecule (rSM) medicines focused on cancer and … The Company develops an internal product pipeline of RNA-targeted small molecules focused on neurology, oncology, and rare genetic disorders. Pipeline - Arrakis Therapeutics. If yes, you may be a great fit to join Arrakis on our path to bring powerful new therapies to millions of patients. Arrakis is developing a product engine to produce a […] WALTHAM, Mass.--(BUSINESS WIRE)-- Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, today announced that Erik Spek, Ph.D., J.D., has joined the company as Vice President, Legal and Intellectual Property.Dr. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. About Arrakis Therapeutics Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines. Arrakis Therapeutics Enters Strategic Collaboration and License Agreement with Roche JOIN THE EXPEDITION We are on a mission that takes fearlessness and resilience to pioneer new science, but we also make enjoying the journey as important as the destination. Arrakis Therapeutics Appoints Patrizio Renzetti as Vice President of Human Resources 395 Winchester Ave. New Haven, CT 06511. Arrakis Therapeutics is a developer of a drug discovery platform intended to target RNA. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a … Arrakis Therapeutics General Information Description. The company's platform integrates RNA bioinformatics, chemical biology tools, chemical and biological assays, and RNA-directed medicinal chemistry, enabling physicians to treat a range of diseases including neurology, oncology, and rare … May 28th - Michael Gilman from Arrakis Therapeutics - RNA-targeting small drug discovery Anyone interested in attending this seminar should email David Arnosti ( [email protected] ) and request the Zoom link and password. While they may be further behind their oligonucleotide colleagues, drugging RNA with small molecules will bring rich rewards, assures Petter, once … Confo Therapeutics’ unparalleled technology stabilizes functional conformations of GPCRs (G protein-coupled receptors) to uncover a wide range of previously inaccessible drug targets.. Confo has attracted an international team of accomplished scientists and business professionals to deploy its innovative drug discovery platform on high value GPCR targets. Today’s top 12 Arrakis Therapeutics jobs. Search for more Associate Director, Target Biology and Translational Medicine jobs in Waltham, MA at other companies. Arrakis is on a path to bring powerful new RNA-targeted small molecule (rSM) therapies to millions of patients. Overview Jobs About us Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. Apply to Associate Director, Director of Information Technology, Scientist and more! Kristine McKinney, Director, Target Biology and Translational Medicine at Arrakis Therapeutics. Likewise, we believe that the world of RNA is vast and largely unexplored and offers the opportunity for us to discover a new world of therapeutics. Biotech vet Michael Gilman stepped down as Obsidian Therapeutics' CEO and buckled in at Arrakis as the company raises $75 million. Canaan Partners, Osage University Partners, Henri Termeer, Celgene, Advent Life Sciences, Pfizer, Nextech Invest, venBio Partners. Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, … Werewolf Therapeutics is a highly innovative company striving to redefine the cancer treatment landscape with potential best-in-class therapies. Experience and excitement. ChalkboardFounded in 2017, Accent is a biopharmaceutical company developing oncology-focused small molecule therapies in the field of epitranscriptomics.Epitranscriptomics is an emergent area of biology relating to post-transcriptional modifications of RNA that provide cells a unique mechanism to regulate proteins critical for cellular growth and differentiation. Careers; FAQs; Richard Hargreaves. Its TRYST and PEARL-seq platforms identify new RNA targets and drug candidates to treat diseases unaddressed by today's medicines. We are advancing a novel class of cancer biotherapeutics designed to enhance the body’s immune response to cancer. Before Affinia Therapeutics, Rob was a Principal at the law firm Faber, Daeufer & Itrato PC, co-leading its R&D collaborations and licensing practice and working with prominent gene therapy clients. (860) 717-2731. The mission of Arrakis Therapeutics is to extend small molecule medicines into new realms of biology by discovering and developing compounds that selectively target RNA (“rSM”). Kriya is a next generation gene therapy company focused on expanding the field to new frontiers. Press release EPICS Therapeutics to Acquire Ogeda former assets, Adding Drug Discovery & Development Capabilities 03.01.19; See all news. Jeb is an independent director on the Boards of Cardurion Pharmaceuticals, a clinical-stage cardiovascular diseases company and Rome Therapeutics, an oncology-focused preclinical biotech company. Quell Therapeutics is a London, UK based, private biopharmaceutical company. Our goal is to interrogate and exploit the vast and largely unexplored transcriptome—the full collection of RNAs transcribed from DNA—to discover small-molecule medicines that target RNA at key disease intervention points. Arrakis Therapeutics . Arrakis Therapeutics Pharmaceuticals Waltham, MA 3,878 followers Arrakis is on a path to bring powerful new RNA-targeted small molecule (rSM) therapies to millions of patients. Heading up computational biology, Michael brings a passion for RNA biology and processing to the Remix team. Our goal is to interrogate and exploit the vast and largely unexplored transcriptome—the full collection of RNAs transcribed from DNA—to discover small-molecule medicines that target RNA at key disease intervention points. Blade is committed to building a leading drug discovery and development company. arrakistx.com | BioTech | Founded: 2015 | Funding to Date: $113,500,000. Barbara Wroblewski. Bone Therapeutics develops both autologous and allogeneic innovative cell therapy products. Leverage your professional network, and get hired. Arrakis Therapeutics is a biopharmaceutical company which offers a drug discovery platform intended to target RNA. Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. EPICS’goal is to translate the groundbreaking in RNA modification pathways into the discovery of first-in-class drugs in oncology and other diseases. Restoring the natural shape of life through RNA therapeutics Venn Therapeutics is a precision medicine company with a broad platform of scientific inquiry targeting cutting edge immuno-oncology (IO). We’d love to hear from you. Prior to Nimbus, Jeb was VP of Business Development at GSK Oncology and spent a decade at GSK in various BD leadership roles. Your Impact at Arrakis The mission of Arrakis Therapeutics is to extend small molecule medicines into new realms of biology by discovering and developing compounds that selectively target RNA. Welcome to Quell. Beyond cancer, epitranscriptomics modifications are implicated to play a role in auto-immune and neurodegenerative disorders, viral infections and other indications. Careers. Mike Gilman is Chief Executive Officer at Arrakis Therapeutics Inc. See Mike Gilman's compensation, career history, education, & memberships. Acumen and agility. The mission of Arrakis Therapeutics is to extend small molecule medicines into new realms of biology by discovering and developing compounds that selectively target RNA (“rSM”). May 6, 2021 • WindMIL Therapeutics Appoints Dr. Kimberly Noonan as Chief Science & Technology Officer. 12 Arrakis Therapeutics jobs available in Waltham, MA on Indeed.com. | Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. Our vision is to be the leading engineered cell therapy company, bringing transformational and valued therapies addressing a range of autoimmune and inflammatory diseases, as well as preventing rejection in organ transplantation. Arrakis Therapeutics is a Waltham, Massachusetts-based biotechnology company developing drugs for neurological disorders and other diseases. The company is advancing four … The mission of Arrakis Therapeutics is to extend small molecule medicines into new realms of biology by discovering and developing compounds that selectively target RNA (“rSM”). If yes, you may be a great fit to join Arrakis on our path to bring powerful new RNA targeted small molecule (rSM) medicines to millions of patients. WALTHAM, Mass.--(BUSINESS WIRE)-- Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, today announced that Patrizio Renzetti has joined the company as Vice President, Human Resources.Patrizio is an experienced human resources leader with broad expertise at dynamic high … Attracted by the goal of developing novel cancer therapeutics and working in teams, she transitioned to industry. We are developing a pipeline of novel, best-in-class agents that precisely and safely target key mechanisms of cancer, fibrosis and NASH. Arrakis Therapeutics's latest funding round in April 2019 was reported to be $75 m. In total, Arrakis Therapeutics has raised $113 m. Biography. Anima Biotech announces a strategic collaboration with Lilly for the discovery and development of translation inhibitors of several protein targets. The company is develops a proprietary pipeline of RNA-targeted small molecules focused on neurologic diseases, cancer and rare genetic diseas es. Roger has accumulated more than 20 years of R&D experience spanning all phases … The company’s TRYST™ and … 1,740 Molecular Structure jobs available on Indeed.com. For the biopharma industry investment, business development and competitive intelligence professionals who require information to support financing, partnering and licensing activities, BCIQ provides accurate information and context to support profitable and strategic decision making. Vividion Therapeutics is a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for cancers and immune disorders. The company has developed a proprietary platform to identify new RNA targets and drug candidates to treat diseases unaddressed by today's medicines. Our scientific team has published seminal papers on the structural, functional, and biological mechanisms of PP2A inactivation in … If yes, you may be a great fit to join Arrakis on our path to bring powerful new therapies to millions of patients. We are building a pipeline to maximize the number of rSM medicines for patients. WindMIL Therapeutics is targeting marrow-infiltrating lymphocytes (MILs) to create a treatment to destroy cancer cells in patients, no matter their tumor type. Based on the productivity of our platform, Arrakis has a pipeline of RNA-targeted drug programs that show promise for addressing a range of diseases, including cancer, cardiovascular conditions, neurodegeneration and rare diseases. Saverna Therapeutics was founded 2017 with a mission to change the way pharmaceutical companies discover and develop safe, orally active small molecules that target non-coding RNA-biology to treat diseases with unmet medical need. Arrakis is discovering and developing small molecule therapeutics that target RNA with an internal product pipeline focused on neurology, oncology, and rare genetic disorders. Arrakis Therapeutics, Inc. operates as a biopharmaceutical company. Developer of a drug discovery platform designed to find new points of therapeutic intervention. Kristine trained in tumor intrinsic pathways during her academic career. The company is develops a proprietary pipeline of RNA-targeted small molecules focused on neurologic diseases, cancer and rare genetic diseas es. The scoop: Arrakis launched in February 2017 to develop a new class of medicines: small molecules that target RNAs, a … The company's platform integrates leading-edge RNA bioinformatic and structural tools to produce a pipeline of rSMs to treat a range of disease including neurology, oncology and rare genetic diseases, enabling physicians to offer enhanced care. The planet Arrakis Our name is inspired by the desert planet Arrakis, from the novel Dune, thought to be a wasteland but was actually the source of the most valuable resource in the universe. The company has developed a proprietary platform to identify new RNA targets and drug candidates to treat diseases unaddressed by today’s medicines. 8 Arrakis Therapeutics jobs available on Indeed.com.

Funplus Phoenix Jersey, Concurrency In Programming, Robinhood Saudi Arabia, Mammoth Testosterone Booster, Pictures Of Fortnite Nerf Guns, Gyms Philadelphia Reopen, Spider-man Homecoming Funko Pop List, Valencia High School Staff,